These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Leukocytapheresis in patients with moderate-severe steroid-dependant ulcerative colitis: clinical response without endoscopic response. Modesto I; Scimeca D; Orlando A; Cottone M Inflamm Bowel Dis; 2006 Oct; 12(10):1009-10. PubMed ID: 17012976 [No Abstract] [Full Text] [Related]
43. Pattern of Inflammation on Surveillance Colonoscopy Does Not Predict Development of Colitis-associated Neoplasia. Jegadeesan R; Navaneethan U; Gutierrez NG; Venkatesh PG; Hammel JP; Sanaka MR; Shen B Inflamm Bowel Dis; 2016 Sep; 22(9):2221-8. PubMed ID: 27542134 [TBL] [Abstract][Full Text] [Related]
44. Review article: evolving concepts in treatment and disease modification in ulcerative colitis. Hanauer SB Aliment Pharmacol Ther; 2008 Mar; 27 Suppl 1():15-21. PubMed ID: 18307645 [TBL] [Abstract][Full Text] [Related]
45. Clinical experience with adalimumab in anti-TNF-naïve patients with ulcerative colitis. Busquets D; Aldeguer X J Crohns Colitis; 2013 Jun; 7(5):e195. PubMed ID: 23219261 [No Abstract] [Full Text] [Related]
46. U.S. Patients with Ulcerative Colitis Do Not Have a Decreased Risk of Diverticulosis. Kinnucan J; Tomal J; Rubin DT Inflamm Bowel Dis; 2015 Sep; 21(9):2154-7. PubMed ID: 26197447 [TBL] [Abstract][Full Text] [Related]
47. Randomized clinical trial of Plantago ovata seeds (dietary fiber) as compared with mesalamine in maintaining remission in ulcerative colitis. Spanish Group for the Study of Crohn's Disease and Ulcerative Colitis (GETECCU). Fernández-Bañares F; Hinojosa J; Sánchez-Lombraña JL; Navarro E; Martínez-Salmerón JF; García-Pugés A; González-Huix F; Riera J; González-Lara V; Domínguez-Abascal F; Giné JJ; Moles J; Gomollón F; Gassull MA Am J Gastroenterol; 1999 Feb; 94(2):427-33. PubMed ID: 10022641 [TBL] [Abstract][Full Text] [Related]
48. Duration of remission and long-term prognosis according to the extent of disease in patients with ulcerative colitis on continuous mesalamine treatment. Bresci G; Parisi G; Capria A Colorectal Dis; 2008 Oct; 10(8):814-7. PubMed ID: 18834420 [TBL] [Abstract][Full Text] [Related]
50. Probiotics for induction of remission in ulcerative colitis. Kaur L; Gordon M; Baines PA; Iheozor-Ejiofor Z; Sinopoulou V; Akobeng AK Cochrane Database Syst Rev; 2020 Mar; 3(3):CD005573. PubMed ID: 32128795 [TBL] [Abstract][Full Text] [Related]
51. Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis. Dignass AU; Bokemeyer B; Adamek H; Mross M; Vinter-Jensen L; Börner N; Silvennoinen J; Tan G; Pool MO; Stijnen T; Dietel P; Klugmann T; Vermeire S; Bhatt A; Veerman H Clin Gastroenterol Hepatol; 2009 Jul; 7(7):762-9. PubMed ID: 19375519 [TBL] [Abstract][Full Text] [Related]
52. Collagenous colitis evolving into ulcerative colitis: a case report and review of the literature. Aqel B; Bishop M; Krishna M; Cangemi J Dig Dis Sci; 2003 Dec; 48(12):2323-7. PubMed ID: 14714620 [No Abstract] [Full Text] [Related]
53. Ulcerative colitis associated with leukocytoclastic vasculitis of the skin. Tripodi Cutrì F; Salerno R; Lo Schiavo A; Gravina AG; Romano M; Ruocco E Dig Liver Dis; 2009 Jul; 41(7):e42-4. PubMed ID: 18799375 [TBL] [Abstract][Full Text] [Related]
54. Quantitive cytokine mRNA expression profiles in the colonic mucosa of patients with steroid naïve ulcerative colitis during active and quiescent disease. Matsuda R; Koide T; Tokoro C; Yamamoto T; Godai T; Morohashi T; Fujita Y; Takahashi D; Kawana I; Suzuki S; Umemura S Inflamm Bowel Dis; 2009 Mar; 15(3):328-34. PubMed ID: 18942752 [TBL] [Abstract][Full Text] [Related]
55. Case of linear IgA bullous dermatosis-involved ulcerative colitis. Taniguchi T; Maejima H; Saito N; Katsuoka K; Haruki S Inflamm Bowel Dis; 2009 Sep; 15(9):1284-5. PubMed ID: 19023862 [No Abstract] [Full Text] [Related]
56. Therapeutic efficacy of leukocytapheresis in a pregnant woman with severe active ulcerative colitis. Okada H; Makidono C; Takenaka R; Hiraoka S; Fujiwara A; Kato J; Kawahara Y; Kawamoto H; Mizuno M; Shiratori Y Digestion; 2006; 74(1):15-8. PubMed ID: 16940730 [TBL] [Abstract][Full Text] [Related]
57. Late-Onset of Acute Severe Ulcerative Colitis: Clinical Case. Dorofeyev AE; Rassokhina OA; Dorofeyeva AA Dig Dis; 2017; 35(1-2):45-49. PubMed ID: 28147350 [TBL] [Abstract][Full Text] [Related]
58. How long is it advisable to prolong maintenance treatment of patients with ulcerative colitis? Ardizzone S; Porro GB Inflamm Bowel Dis; 2008 Oct; 14 Suppl 2():S238-9. PubMed ID: 18816705 [No Abstract] [Full Text] [Related]
59. Oral mesalamine prodrug approved for active ulcerative colitis. Am J Health Syst Pharm; 2000 Sep; 57(17):1570. PubMed ID: 10984803 [No Abstract] [Full Text] [Related]
60. Long-term safety and tolerability of once-daily mesalamine granules in the maintenance of remission of ulcerative colitis. Lichtenstein GR; Barrett AC; Bortey E; Paterson C; Forbes WP Inflamm Bowel Dis; 2014 Aug; 20(8):1399-406. PubMed ID: 24874460 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]